Clinical trials: Interstitial Cystitis, Chronic
Interstitial Cystitis, Painful Bladder Syndrome
Efficacy and Safety Study of Uracyst to Treat Interstitial Cystitis/Painful Bladder Syndrome
A new device for interstitial cystitis is compared to inactive control to determine if it is safe and effective. The study lasts approximately 7 weeks with a 19-week follow-up period.
- Trial name
- NCT00919113
- Testing
- 2% sodium chondroitin sulfate
- Where
- 20 sites in United States
- Volunteers
- 98 people
- Sponsor
- Watson Pharmaceuticals
Bladder Pain Syndrome, Interstitial Cystitis
A Study to Investigate Efficacy, Safety, Pharmacodynamics and Pharmacokinetics of ASP6294 in the Treatment of Female Subjects With Bladder Pain Syndrome/Interstitial Cystitis
The purpose of this study is to investigate efficacy, safety and tolerability of ASP6294 in female participants with Bladder Pain Syndrome/Interstitial Cystitis (BPS/IC).
- Trial name
- SERENITY (NCT03282318)
- Testing
- ASP6294
- Where
- 28 sites in Belgium, Czechia and 8 more
- Volunteers
- 119 people
- Sponsor
- Astellas Pharma Europe B.V.
Bladder Pain Syndrome
The Safety and Efficacy of Gefapixant (AF-219/MK-7264) in Female Participants With Interstitial Cystitis /Bladder Pain Syndrome (MK-7264-005)
The purpose of this study is to assess the efficacy of gefapixant (AF-219/MK-7264) in female participants with moderate to severe pain associated with interstitial cystitis/bladder pain syndrome (IC/BPS) after 4 weeks of…
- Trial name
- NCT01569438
- Testing
- Gefapixant
- Where
- 41 sites in United States
- Volunteers
- 107 people
- Sponsor
- Afferent Pharmaceuticals, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Interstitial Cystitis
Safety Study of Single Intravesical Doses of TTI-1612 in Women With Interstitial Cystitis/Bladder Pain Syndrome
The purpose of this study is to determine the safety and pharmacokinetics of TTI-1612 in women with interstitial cystitis/bladder pain syndrome.
- Trial name
- NCT01559961
- Testing
- TTI-1612
- Where
- 4 sites in Canada
- Volunteers
- 28 people
- Sponsor
- Trillium Therapeutics Inc.
Chronic Interstitial Cystitis
A Safety, Tolerability and Preliminary Efficacy Study of LiRIS® 400 mg in Women With Interstitial Cystitis (IC) and Hunner's Lesions
The purpose of the study is to evaluate if LiRIS 400 mg is safe and tolerable when administered to women with Interstitial Cystitis with Hunner's lesions, and to evaluate any change in the bladder or in IC symptoms, following…
- Trial name
- NCT01879683
- Testing
- LiRIS® 400 mg
- Where
- 2 sites in United States
- Volunteers
- 10 people
- Sponsor
- Allergan
Interstitial Cystitis, Chronic Pain
A Novel Medical System for Quantitative Diagnosis and Personalized Precision Botulinum Neurotoxin Injection in Chronic Pelvic Pain Management
The purpose of this study is to evaluate if it is possible to use intravaginal high-density surface electromyography to guide Botulinum neurotoxin (BoNT) injection to treat pelvic floor muscle overactivity that complicates…
- Conditions
- Interstitial Cystitis, Chronic Pain, Pelvic Floor; Relaxation, Pelvic Floor Disorders
- Trial name
- NCT05062902
- Testing
- High Density Surface Electromyographic, precision botulinum neurotoxin injection guidance medical device, Botulinum Neurotoxin
- Where
- United States
- Volunteers
- 46 people
- Sponsor
- HillMed Inc.
Urinary Tract Infections, Prostatitis
Rapid Molecular Organism Identification and Mixed Flora Antibiotic Resistance Profiling (MixAR) Prospective Study
In this protocol, investigators are examining the ability for a novel multiplex PCR assay with mixed floral antibiotic resistance profiling is safe and increases effective treatment for urinary tract infections in a urology…
- Conditions
- Urinary Tract Infections, Prostatitis, Interstitial Cystitis
- Trial name
- RapIDMixAR (NCT03931538)
- Testing
- Guidance 4.0 PCR test, Urine Culture
- Where
- United States
- Volunteers
- 2,511 people
- Sponsor
- Pathnostics
Interstitial Cystitis, Bladder Pain Syndrome
Engage 24: Evaluation of the Safety and Effectiveness of URG101 in Subjects With Interstitial Cystitis/Bladder Pain Syndrome
The purpose of this study is to determine if the combination product (URG101) is safe and effective versus its individual components (Heparin Sodium and Lidocaine Hydrochloride) for the treatment of Interstitial Cystitis/Bladder…
- Trial name
- NCT02591199
- Testing
- URG101, Lidocaine, Heparin
- Where
- 11 sites in United States
- Volunteers
- 91 people
- Sponsor
- Urigen
Interstitial Cystitis/Bladder Pain Syndrome
Study of V117957 in Interstitial Cystitis/Bladder Pain Syndrome
The purpose of this study is to evaluate the safety, tolerability and efficacy of V117957 in subjects with interstitial cystitis/bladder pain syndrome, compared to placebo.
- Trial name
- NCT06285214
- Testing
- V117957
- Where
- 24 sites in United States
- Volunteers
- 47 people
- Sponsor
- Imbrium Therapeutics
Interstitial Cystitis, Bladder Pain Syndrome
Efficacy and Safety of 2 Doses of AQX-1125 in Subjects With Interstitial Cystitis / Bladder Pain Syndrome
This study evaluates the effects of two doses of oral AQX-1125 on bladder pain and other urinary symptoms in subjects with interstitial cystitis/bladder pain syndrome.
- Conditions
- Interstitial Cystitis, Bladder Pain Syndrome, Painful Bladder Syndrome, Chronic Interstitial Cystitis
- Trial name
- LEADERSHIP 301 (NCT02858453)
- Testing
- AQX-1125 100 mg, AQX-1125 200 mg
- Where
- 120 sites in United States, Belgium and 10 more
- Volunteers
- 433 people
- Sponsor
- Aquinox Pharmaceuticals (Canada) Inc.
Interstitial Cystitis, Bladder Pain Syndrome
Safety, Efficacy, and Frequency of Administration of VNX001 in the Treatment of Interstitial Cystitis / Bladder Pain Syndrome (IC/BPS)
This is an open-label study that will enroll participants with Interstitial Cystitis / Bladder Pain Syndrome (IC/BPS). The study will assess PRN (as needed) dosing of up to 6 intravesical (via catheter) doses of VNX001 (study…
- Trial name
- NCT06394830
- Testing
- VNX001
- Where
- 5 sites in United States
- Volunteers
- 50 people
- Sponsor
- Vaneltix Pharma, Inc.
Interstitial Cystitis/Bladder Pain Syndrome (IC/BPS)
Study of BOTOX Injections to Assess Change in Disease Activity and Adverse Events in Adult Female Participants With Interstitial Cystitis/Bladder Pain Syndrome (IC/BPS)
Interstitial Cystitis/Bladder Pain Syndrome (IC/BPS) is a chronic and debilitating urological complex of disorders characterized by symptoms of bladder pain or discomfort, mostly upon bladder filling, and often accompanied by…
- Trial name
- IC/BPS POC (NCT05141006)
- Testing
- BOTOX
- Where
- 43 sites in United States, Canada
- Volunteers
- 83 people
- Sponsor
- AbbVie
Interstitial Cystitis
Phase II Study Efficacy and Safety of Two Dosing Regimens of MN-001 in Patients With Interstitial Cystitis
To evaluate the safety and efficacy of 8 weeks of treatment with MN-001 at 500 mg bid, 500 mg once daily vs. placebo in patients with Interstitial Cystitis.
- Trial name
- NCT00295854
- Testing
- MN-001 BID, MN-001
- Where
- 28 sites in United States
- Volunteers
- 296 people
- Sponsor
- MediciNova
Interstitial Cystitis, Bladder Pain Syndrome
Safety and Efficacy Study of VNX001 Compared to Its Individual Components (Lidocaine and Heparin) or Placebo in Subjects With IC/BPS
This is a Phase 2, prospective, randomized, double-blind, placebo-controlled, multi-center, single-dose, pharmacodynamic study designed to evaluate the efficacy and safety of the combination product (VNX001) versus placebo and…
- Trial name
- NCT05737121
- Testing
- VNX001, Lidocaine, Heparin
- Where
- 14 sites in United States
- Volunteers
- 120 people
- Sponsor
- Vaneltix Pharma, Inc.
Hunner Type Interstitial Cystitis
A Clinical Study of ONO-1110 in Patients With Hunner Type Interstitial Cystitis
To Evaluate the Efficacy and Safety of ONO-1110 in Patients with Hunner Type Interstitial Cystitis
- Trial name
- NCT06752603
- Testing
- ONO-1110
- Where
- 20 sites in Japan
- Volunteers
- 57 people
- Sponsor
- Ono Pharmaceutical Co., Ltd.
Painful Bladder Syndrome, Interstitial Cystitis
Study of URG101 in Painful Bladder Syndrome and Interstitial Cystitis
A double-blind, placebo-controlled study to evaluate changes in pain, urgency and urinary frequency following administration of URG101 compared to placebo.
- Conditions
- Painful Bladder Syndrome, Interstitial Cystitis, Bladder Pain Syndrome
- Trial name
- NCT00517868
- Testing
- URG101
- Where
- 6 sites in United States
- Volunteers
- 28 people
- Sponsor
- Urigen
Cystitis, Interstitial
Safety and Efficacy of AGN 203818 for Pain Associated With Painful Bladder Syndrome/Interstitial Cystitis
This study will explore the safety and effectiveness of different doses of AGN 203818 in treating the pain associated with painful bladder syndrome/interstitial cystitis
- Trial name
- NCT00380783
- Testing
- AGN 203818
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Allergan
Interstitial Cystitis
A Pilot Clinical Investigation of the Efficacy and Safety of Uracyst® Versus Placebo in Patients With Interstitial Cystitis/Painful Bladder Syndrome.
This is a pilot clinical investigation. Patients who meet the eligibility criteria and provide signed informed consent will be randomized to receive either an active product (Uracyst®) or placebo intravesically via a bladder…
- Trial name
- NCT00527917
- Testing
- Uracyst
- Where
- 13 sites in Canada
- Volunteers
- 65 people
- Sponsor
- Watson Pharmaceuticals
Interstitial Cystitis, Bladder Pain Syndrome
Efficacy and Safety of AQX-1125 in IC/BPS
The primary objective of this study is to evaluate the effect of 6 weeks of treatment with once daily administration of AQX-1125 compared to placebo on average daily pain in subjects with interstitial cystitis/bladder pain…
- Trial name
- LEADERSHIP (NCT01882543)
- Testing
- AQX-1125
- Where
- 29 sites in United States, Canada
- Volunteers
- 69 people
- Sponsor
- Aquinox Pharmaceuticals (Canada) Inc.
Interstitial Cystitis
Effectiveness and Safety Study of Pentosan Polysulfate Sodium for the Treatment of Interstitial Cystitis
The purpose of this study is to evaluate the safety and effectiveness of pentosan polysulfate sodium 100 mg once a day, pentosan polysulfate sodium 100 mg three times a day, and placebo for 24 weeks for the relief of bladder pain…
- Trial name
- NCT00086684
- Testing
- Pentosan polysulfate sodium 100 mg
- Where
- 65 sites in United States, Canada
- Volunteers
- 369 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.